Tamiflu touted for child use

Nov 16, 2007

The maker of the anti-viral Tamiflu said the drug is effective for treatment and prevention of influenza in young children.

Data presented at the World Society for Pediatric Infectious Disease meeting in Bangkok this week said Tamiflu (oseltamivir) significantly reduces illness severity and duration of influenza in children ages 1 and older, particularly if given within 24 hours of symptom onset, Roche pharmaceuticals said Thursday in a release.

Roche pharmaceuticals said it will offer child-sized Tamiflu capsules of 30 mg and 45 mg doses to provide easier and more convenient dosing by parents.

The company said Tamiflu was shown to reduce influenza severity by 52 percent, and illness duration was reduced by 34 percent if treatment was started within 24 hours of onset.

Copyright 2007 by United Press International

Explore further: FDA approves hard-to-abuse narcotic painkiller

add to favorites email to friend print save as pdf

Related Stories

New research assesses use of Tamiflu, Relenza to prevent flu

Aug 03, 2009

Two common anti-influenza drugs — Relenza and Tamiflu — appear equally effective at preventing common flu symptoms when given before infection, say researchers from the Stanford University School of Medicine. However, ...

TGen seeks emergency FDA approval of new swine flu test

Oct 29, 2009

The Phoenix-based non-profit Translational Genomics Research Institute (TGen) announced today that, along with a business collaborator, it will submit a request to the U.S. Food and Drug Administration for emergency use of ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

10 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

11 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

11 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

12 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments : 0